Intravenous Infusions Plc (GHSE:IIL)

Intravenous Infusions Income Statement

Financials in millions GHS. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	9.3	24.94	31.42	20.36	22.67
Revenue Growth (YoY)	-62.70%	-20.61%	54.34%	-10.21%	9.69%
Cost of Revenue	7.99	13.39	14.14	11.6	12.04
Gross Profit	1.31	11.55	17.28	8.76	10.63
Selling, General & Admin	8.71	10.07	9.96	11.39	8.86
Amortization of Goodwill & Intangibles	0.01	0.01	0.01	0	-
Operating Expenses	9.27	10.73	10.76	11.96	9.41
Operating Income	-7.96	0.82	6.52	-3.21	1.23
Interest Expense	-0.11	-0.14	-0.72	-0.39	-0.15
Other Non Operating Income (Expenses)	2.29	-1.17	-2.35	0.06	0.36
EBT Excluding Unusual Items	-5.78	-0.49	3.44	-3.54	1.43
Gain (Loss) on Sale of Assets	-	0.01	0.05	0	-
Pretax Income	-5.78	-0.49	3.49	-3.53	1.43
Income Tax Expense	-1.15	0.16	0.95	-0.02	0.29
Net Income	-4.63	-0.64	2.54	-3.51	1.15
Net Income to Common	-4.63	-0.64	2.54	-3.51	1.15
Net Income Growth	-	-	-	-	-20.99%
Shares Outstanding (Basic)	274	274	274	274	274
Shares Outstanding (Diluted)	274	274	274	274	274
EPS (Basic)	-0.02	-0.00	0.01	-0.01	0.00
EPS (Diluted)	-0.02	-0.00	0.01	-0.01	0.00
EPS Growth	-	-	-	-	-21.00%
Free Cash Flow	-0.87	5.59	2.39	0.45	-3.86
Free Cash Flow Per Share	-0.00	0.02	0.01	0.00	-0.01
Dividend Per Share	-	-	0.003	-	-
Gross Margin	14.07%	46.31%	55.01%	43.02%	46.91%
Operating Margin	-85.52%	3.28%	20.74%	-15.76%	5.42%
Profit Margin	-49.78%	-2.58%	8.10%	-17.24%	5.06%
Free Cash Flow Margin	-9.38%	22.43%	7.59%	2.22%	-17.03%
EBITDA	-7.41	1.47	7.31	-2.64	1.76
EBITDA Margin	-79.63%	5.89%	23.27%	-12.98%	7.79%
D&A For EBITDA	0.55	0.65	0.79	0.56	0.54
EBIT	-7.96	0.82	6.52	-3.21	1.23
EBIT Margin	-85.52%	3.28%	20.74%	-15.76%	5.42%
Effective Tax Rate	-	-	27.17%	-	19.97%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.